Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 14, 2025
DataAggregated Company Financials
Companies564
- 7D0.09%
- 3M-10.4%
- 1Y-14.9%
- YTD-8.4%
Over the last 7 days, the Biotech industry has remained flat, although notably Gilead Sciences gained 3.6%. Unfortunately though, the industry is down 15% over the past 12 months. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 14 May 2025 | US$900.2b | US$155.8b | -US$24,630,928,316.59 | 17.1x | -36.5x | 5.8x |
| Fri, 11 Apr 2025 | US$740.3b | US$118.7b | -US$36,946,322,041.25 | 20.1x | -20x | 6.2x |
| Sun, 09 Mar 2025 | US$845.7b | US$119.0b | -US$37,235,296,640.99 | 17.2x | -22.7x | 7.1x |
| Tue, 04 Feb 2025 | US$1.0t | US$149.5b | -US$26,288,414,233.30 | 17x | -38.2x | 6.7x |
| Thu, 02 Jan 2025 | US$965.8b | US$149.6b | -US$26,363,617,914.14 | 16.9x | -36.6x | 6.5x |
| Sat, 30 Nov 2024 | US$1.0t | US$150.0b | -US$26,595,948,620.50 | 16.4x | -39.2x | 6.9x |
| Mon, 28 Oct 2024 | US$888.8b | US$113.1b | -US$36,033,068,263.01 | 20.6x | -24.7x | 7.9x |
| Wed, 25 Sep 2024 | US$898.3b | US$113.2b | -US$35,988,802,771.93 | 21.3x | -25x | 7.9x |
| Fri, 23 Aug 2024 | US$909.8b | US$113.1b | -US$35,862,506,910.65 | 23.2x | -25.4x | 8x |
| Sun, 21 Jul 2024 | US$1.2t | US$164.5b | -US$28,073,816,966.89 | 29x | -42.5x | 7.3x |
| Tue, 18 Jun 2024 | US$1.2t | US$164.4b | -US$27,975,455,242.00 | 27.2x | -41.4x | 7x |
| Thu, 16 May 2024 | US$1.1t | US$164.7b | -US$27,078,015,634.20 | 27.4x | -41.8x | 6.9x |
| Sat, 13 Apr 2024 | US$1.1t | US$164.3b | -US$23,403,359,856.87 | 21.1x | -48x | 6.8x |
| Mon, 11 Mar 2024 | US$1.2t | US$167.3b | -US$22,140,783,177.03 | 19x | -54x | 7.1x |
| Wed, 07 Feb 2024 | US$1.3t | US$196.3b | -US$18,462,068,032.85 | 18.2x | -71.9x | 6.8x |
| Fri, 05 Jan 2024 | US$1.4t | US$204.8b | -US$22,497,844,900.00 | 20.7x | -63.1x | 6.9x |
| Sun, 03 Dec 2023 | US$1.3t | US$204.7b | -US$22,041,230,456.00 | 19x | -57.3x | 6.2x |
| Tue, 31 Oct 2023 | US$1.2t | US$206.7b | -US$15,128,771,668.00 | 16.8x | -79x | 5.8x |
| Thu, 28 Sep 2023 | US$1.3t | US$207.3b | -US$12,783,837,188.00 | 17.2x | -99.3x | 6.1x |
| Sat, 26 Aug 2023 | US$1.3t | US$207.6b | -US$12,451,867,612.00 | 17.5x | -102.5x | 6.1x |
| Mon, 24 Jul 2023 | US$1.2t | US$186.6b | -US$16,026,393,300.00 | 12.8x | -72x | 6.2x |
| Wed, 21 Jun 2023 | US$1.2t | US$186.2b | -US$16,035,932,986.00 | 12.3x | -71.9x | 6.2x |
| Fri, 19 May 2023 | US$1.1t | US$186.0b | -US$15,909,132,064.00 | 13x | -71.7x | 6.1x |
| Sun, 16 Apr 2023 | US$1.2t | US$198.5b | -US$3,246,996,905.00 | 14.1x | -361.6x | 5.9x |
| Tue, 14 Mar 2023 | US$1.1t | US$199.5b | -US$4,680,634,660.00 | 15x | -238.6x | 5.6x |
| Thu, 09 Feb 2023 | US$1.1t | US$202.5b | US$1.3b | 16.3x | 848.7x | 5.6x |
| Sat, 07 Jan 2023 | US$1.2t | US$203.3b | US$1.6b | 14.7x | 735.3x | 5.8x |
| Mon, 05 Dec 2022 | US$1.2t | US$202.6b | US$1.4b | 15.1x | 844.7x | 5.8x |
| Wed, 02 Nov 2022 | US$1.1t | US$205.7b | US$7.3b | 14.3x | 150.3x | 5.3x |
| Fri, 30 Sep 2022 | US$1.0t | US$206.1b | US$5.7b | 14.9x | 180.5x | 5x |
| Sun, 28 Aug 2022 | US$1.0t | US$206.2b | US$7.3b | 15.2x | 143x | 5x |
| Tue, 26 Jul 2022 | US$1.1t | US$211.4b | US$11.3b | 15.9x | 94.9x | 5.1x |
| Thu, 23 Jun 2022 | US$998.5b | US$212.5b | US$11.1b | 15.1x | 90x | 4.7x |
| Sat, 21 May 2022 | US$1.0t | US$212.3b | US$10.8b | 15.1x | 93.7x | 4.8x |
Price to Earnings Ratio
93.7x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 5.26% | |
| Healthcare | -1.60% | |
| Biotech | 0.088% | |
| Biotech | 0.088% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GILD Gilead Sciences | US$101.43 | 3.6% +US$4.2b | 49.9% | PE21.2x | |
| REGN Regeneron Pharmaceuticals | US$574.16 | 2.8% +US$1.7b | -41.7% | PE13.5x | |
| ABBV AbbVie | US$188.00 | 0.5% +US$1.0b | 16.3% | PE79.9x | |
| BIIB Biogen | US$123.16 | 5.4% +US$929.0m | -45.7% | PE12.2x | |
| PTCT PTC Therapeutics | US$46.39 | 28.2% +US$808.4m | 48.8% | PE6.2x |
